Publications en collaboration avec des chercheurs de Hospital Universitari de Bellvitge (43)

2024

  1. Congestion as a crucial factor determining albuminuria in patients with cardiorenal disease

    Clinical Kidney Journal, Vol. 17, Núm. 6

  2. Risk factors for progression in KDOQI stage 3 Chronic Kidney Disease (PROGRESER study)

    Nefrologia, Vol. 44, Núm. 5, pp. 689-699

2023

  1. Cardiorenal benefits of finerenone: protecting kidney and heart

    Annals of Medicine, Vol. 55, Núm. 1, pp. 502-513

  2. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

    Journal of Clinical Medicine, Vol. 12, Núm. 1

  3. Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone

    Expert Review of Clinical Pharmacology, Vol. 16, Núm. 6, pp. 519-531

  4. Sex differences in Cardiorenal Syndrome: Insights from CARDIOREN Registry

    Current Heart Failure Reports, Vol. 20, Núm. 3, pp. 157-167

2022

  1. Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes

    Journal of Clinical Medicine, Vol. 11, Núm. 11

2021

  1. Optimizing the timing of nephrology referral for patients with diabetic kidney disease

    Clinical Kidney Journal, Vol. 14, Núm. 1, pp. 5-8

2020

  1. Association of a single nucleotide polymorphism combination pattern of the Klotho gene with non-cardiovascular death in patients with chronic kidney disease

    Clinical Kidney Journal, Vol. 13, Núm. 6, pp. 1017-1024

  2. GLP-1 receptor agonists and diabetic kidney disease: A call of attention to nephrologists

    Journal of Clinical Medicine, Vol. 9, Núm. 4

  3. SGLT2 inhibitors for non-diabetic kidney disease: Drugs to treat CKD that also improve glycaemia

    Clinical Kidney Journal, Vol. 13, Núm. 5, pp. 728-733

  4. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 35, Núm. 1, pp. i13-i23

2019

  1. Association of candidate gene polymorphisms with chronic kidney disease: Results of a case-control analysis in the NEFRONA cohort

    Frontiers in Genetics, Vol. 10, Núm. FEB

  2. Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: What was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?

    Clinical Kidney Journal, Vol. 12, Núm. 3, pp. 313-321

  3. Will the new hypoglycaemic agents be effective on renal and cardiovascular protection in diabetes and renal diabetic disease?

    Nefrologia, Vol. 39, Núm. 1, pp. 3-10

2018

  1. Different rates of progression and mortality in patients with chronic kidney disease at outpatient nephrology clinics across Europe

    Kidney International, Vol. 93, Núm. 6, pp. 1432-1441

  2. Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease

    Diabetes Care, Vol. 41, Núm. 8, pp. 1817-1820

2017

  1. Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: The NEFRONA study

    Nephrology Dialysis Transplantation, Vol. 32, Núm. 3, pp. 513-520

2015

  1. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease

    Nephrology Dialysis Transplantation, Vol. 30, Núm. 7, pp. 1176-1185

  2. Nephroprotection by hypoglycemic agents: Do we have supporting data?

    Journal of Clinical Medicine, Vol. 4, Núm. 10, pp. 1866-1889